tolazamide has been researched along with Huntington Disease in 1 studies
Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, A | 1 |
| Sarkar, S | 1 |
| Cuddon, P | 1 |
| Ttofi, EK | 1 |
| Saiki, S | 1 |
| Siddiqi, FH | 1 |
| Jahreiss, L | 1 |
| Fleming, A | 1 |
| Pask, D | 1 |
| Goldsmith, P | 1 |
| O'Kane, CJ | 1 |
| Floto, RA | 1 |
| Rubinsztein, DC | 1 |
1 other study available for tolazamide and Huntington Disease
| Article | Year |
|---|---|
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imi | 2008 |